Heidelberg Engineering, STAAR, Ziemer to showcase latest technologies at ESCRS 2025
Heidelberg Engineering, STAAR Surgical, and Ziemer Ophthalmic Systems are set to present their latest advancements in cataract and refractive surgery at the 43rd ESCRS Congress in Copenhagen. Heidelberg Engineering will launch a new ANTERION software update with improved cataract app functionality, while STAAR Surgical will highlight its EVO ICL product line and present multiple papers and posters. Ziemer Ophthalmic Systems will introduce innovations like CLEAR Supra, FEMTO-CAIRS, AQUA LASIK with AQUARIUZ, and the CLARIGS operating environment.
STAAR Surgical Co highlights its vision correction technology as investors weigh long-term growth
STAAR Surgical Co (ISIN US8577001096) specializes in implantable collamer lenses for refractive vision correction, positioning itself in the growing market for advanced eye surgery. The company's business model focuses on supplying high-value medical devices to eye care professionals for correcting conditions like myopia and astigmatism. Investors are evaluating the long-term demand for these solutions, taking into account factors like revenue growth, regulatory developments, and market penetration.
3 Reasons to Avoid STAA and 1 Stock to Buy Instead
This article recommends avoiding STAAR Surgical (STAA) despite its recent stock gains, citing three main reasons: declining revenue, a dropping free cash flow margin, and a decrease in Return on Invested Capital (ROIC). The author suggests better investment opportunities exist and advises looking into a dominant software business and StockStory's top 5 growth stocks instead.
Top Intraocular Lens Market Companies Driving Innovation
The global Intraocular Lens (IOL) Market is experiencing significant growth, projected to reach USD 11.19 Billion by 2035 from USD 5.97 Billion in 2025, driven by the increasing prevalence of cataracts and presbyopia, an aging population, and technological advancements. Key market players like Alcon Inc., Johnson & Johnson Vision, and Bausch + Lomb are leading innovation with advanced IOLs and strategic acquisitions. The future outlook points to continued demand for novel IOL options and personalized vision restoration solutions.
How Staar Surgical Company (STAA) Affects Rotational Strategy Timing
This article analyzes Staar Surgical Company (STAA) through an AI model, revealing strong near-term sentiment but neutral mid and long-term outlooks. It highlights a significant short setup with a 67.7:1 risk-reward ratio targeting a 19.2% downside. The analysis provides three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis, emphasizing real-time signals and risk management.
STAAR Surgical Company Actuals & Estimates (NASDAQ:STAA)
This article provides an overview of STAAR Surgical Company (NASDAQ: STAA) financial performance, stock price data, and analyst forecasts. It covers key metrics such as current stock price, historical highs and lows, market capitalization, volatility, and details on its latest earnings and revenue reports. The information is presented to help investors understand the company's financial health and future outlook.
Price to book forward of STAAR Surgical Company – NASDAQ:STAA
This page provides financial data for STAAR Surgical Company (NASDAQ: STAA), specifically focusing on its price-to-book forward ratio. The content seems to be an excerpt from a financial data platform, likely TradingView, presenting the stock's financial overview without detailed figures. It indicates that the market is closed, with no trades currently displayed.
What STAAR Surgical (STAA)'s New Shelf Registration and Equity Plan Expansion Means For Shareholders
STAAR Surgical (STAA) recently filed a US$110.604 million shelf registration for 3,900,000 common shares and expanded its Omnibus Equity Incentive Plan by the same amount following shareholder approval. This move aims to provide financial flexibility and align leadership incentives with long-term company performance, although near-term challenges like China's market volatility remain key swing factors. The expansion allows for new equity awards to directors, reinforcing management's commitment during a period of inventory reset and growth acceleration in other regions.
Staar Surgical Shareholders Approve Expanded Equity Incentive Plan
Staar Surgical shareholders approved an expanded equity incentive plan, reserving an additional 3.9 million shares for issuance, during their 2026 Annual Meeting. They also re-elected seven directors and ratified BDO USA, P.C. as the independent registered public accounting firm. This move signifies the company's commitment to using stock-based incentives to align employee and management interests with long-term shareholder value.
Form 4 STAAR Surgical Company For: 23 June By Investing.com
This article reports on a Form 4 filing for STAAR Surgical Company (STAA) dated June 23. This financial filing indicates insider transactions or changes in beneficial ownership. The article also provides key market data, including various indices, commodities, and stock performances.
Director of STAAR Surgical (NASDAQ: STAA) receives grant of 11,145 stock options
Christopher Min Fang Wang, a director of STAAR Surgical (NASDAQ: STAA), was granted 11,145 stock options with an exercise price of $29.12 per share. These options are part of his compensation, not an open-market transaction, and will vest fully on the earlier of June 18, 2027, or the company’s 2026 annual meeting of shareholders, expiring on June 18, 2036. This grant aims to align the director's interests with shareholders and encourage continued service.
Director Neal Bradsher granted 11,145 STAAR Surgical (STAA) stock options
STAAR Surgical director Neal C. Bradsher received a grant of 11,145 stock options as director compensation. The options have an exercise price of $29.12 per share and will expire on June 18, 2036. They will vest on the earlier of June 18, 2027, or the company's next annual shareholder meeting, provided Bradsher continues his service.
Form 4 STAAR Surgical Company For: 22 June By Investing.com
This article reports on the filing of a Form 4 for STAAR Surgical Company on June 22nd, as noted by Investing.com. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by officers, directors, or 10% shareholders. The article does not provide specifics of the Form 4. This brief update is contextualized amidst various market data and news headlines.
STAAR Surgical (STAA) director awarded 11,145 stock options at $29.12 strike
STAAR Surgical director Richard T. LeBuhn was granted 11,145 stock options at an exercise price of $29.12 per share as part of his director compensation. These options will vest by June 18, 2027, or the company's next annual shareholder meeting, contingent on his continued service. LeBuhn also holds existing options for 7,524 shares at an $18.46 exercise price which are already exercisable.
Intraocular Lens Market to Witness Transformational Growth Opportunities by 2032 – DelveInsight | Johnson & Johnson, Alcon, Bausch & Lomb, ZEISS Group, STAAR Surgical, Hoya Corporation
The global Intraocular Lens (IOL) market, valued at USD 4,648.96 million in 2024, is projected to reach USD 7,414.66 million by 2032, driven by increasing eye-related disorders, technological advancements, and rising awareness. Key players like Johnson & Johnson, Alcon, and Bausch & Lomb are introducing new IOL technologies, with North America expected to lead the market due to its advanced healthcare infrastructure and large patient pool. Despite promising growth, challenges such as post-operative complications and limited insurance coverage for premium lenses remain.
[Form 4] STAAR SURGICAL CO Insider Trading Activity
STAAR Surgical director Lilian Yansheng Zhou reported acquisition or exercise transactions in a Form 4 filing. Zhou received new equity awards, including options to purchase 5,572 shares at $29.12 and 3,091 restricted stock units, as part of the company’s annual non-employee director compensation for the 2026-2027 term. Both the options and RSUs are set to vest in full on June 18, 2027, or the company's 2027 Annual Meeting of Shareholders.
STAAR Surgical (STAA) adds 3.9M plan shares, elects board and ratifies BDO
STAAR Surgical Company's shareholders approved substantial measures at their 2026 Annual Meeting. They voted to increase the shares reserved for their Omnibus Equity Incentive Plan by 3.9 million, elected seven directors, and ratified BDO USA, P.C. as the independent public accounting firm. Additionally, shareholders provided a non-binding advisory approval for the compensation of the company’s named executive officers.
Staar Surgical | 4: Statement of changes in beneficial ownership of securities-Director BROADWOOD PARTNERS, L.P.
This document is a statement of changes in beneficial ownership of securities for Staar Surgical, specifically related to Director BROADWOOD PARTNERS, L.P. It is a mandatory filing to report transactions involving company stock by insiders.
STAAR Surgical Co (STAA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of STAAR Surgical Co (STAA)'s revenue breakdown by region. As of the updated figures on April 6, the company's revenue primarily comes from "Others" (39.19%), China (32.48%), Japan (18.90%), and the U.S. (9.42%). The article notes that relevant data for business segments and future fiscal years (FY2025) have not yet been disclosed by the company.
STAAR Surgical (STAA) Stock Could Be 4.4% Undervalued Despite Its Rich P S Multiple
STAAR Surgical (STAA) is viewed as potentially 4.4% undervalued based on a fair value estimate of $29.67 compared to its current price of $28.37, despite a rich P/S multiple of 4.9x, which is higher than peers and the industry average. The company has strong cash reserves and no debt, providing a solid financial foundation, but faces risks like weak consumer confidence in China and reliance on a single distributor there. Analysts' valuation hinges on future execution, improved margins, and continued premium pricing for growth.
STAAR Surgical (STAA) Stock Could Be 4.4% Undervalued Despite Its Rich P S Multiple
STAAR Surgical (STAA) stock is drawing investor attention as it's priced slightly below its fair value estimate despite a high P/S ratio compared to peers. The company has strong financial reserves and no debt, which supports its potential for growth, but faces risks from its reliance on a single distributor in China. Investors are paying a premium for expected future growth, raising questions about whether execution will support this valuation.
Director Lilian Zhou of STAAR Surgical (STAA) receives 3,530-share stock award
STAAR Surgical director Lilian Yansheng Zhou was awarded 3,530 shares of common stock on June 12, 2026, as a grant or award-type transaction. The shares were valued at a weighted average price of $28.2904, based on multiple trades between $28.215 and $28.35. Following this acquisition, Zhou directly holds 8,101 shares of STAAR Surgical common stock.
STAAR Surgical’s Standout Q1 Raises Questions On Sustainability And Valuation
STAAR Surgical reported outstanding Q1 results with a 120% revenue increase year-on-year, significantly beating analyst estimates and demonstrating strong business momentum. Despite the strong performance, the stock's recent momentum is down 11.5% over the last 30 days, and its valuation is seen as close to fair value by Simply Wall St. Investors are now focused on the sustainability of this growth and how it aligns with the company's current stock price and long-term track record.
STAAR Surgical’s Standout Q1 Raises Questions On Sustainability And Valuation
STAAR Surgical reported exceptional Q1 results with revenue increasing 120% year-on-year, outperforming peers in growth. While the stock has seen significant short-term gains, its longer-term performance has been weaker, prompting questions about the sustainability of this quarter's success. The article suggests investors monitor future revenue, margins, and guidance, noting that despite an impressive Q1, the stock has dipped recently and is trading near its estimated fair value.
STAAR Surgical Company Stock 12‑Month Price Target Raised to $30.5, Implies 6% Upside
STAAR Surgical Company's average 12-month price target has been increased from $29.67 to $30.5 by 8 analysts, suggesting a 6% potential upside from its June 11 closing price. The consensus rating among 11 covering analysts has shifted to "Buy", comprising 3 Buys, 8 Holds, and 0 Sells. Investors can find more detailed price target data and track analyst recommendations on TradingView's Forecasts tab and News Flow.
Medical Devices & Supplies - Specialty Stocks Q1 Earnings: STAAR Surgical (NASDAQ:STAA) Firing on All Cylinders
STAAR Surgical (NASDAQ:STAA) reported strong Q1 earnings, with revenues up 120% year-on-year, significantly exceeding analyst expectations. This performance made it the top performer among its peers in the medical devices & supplies specialty sector, which as a group also saw revenues beat consensus estimates. While other companies like Globus Medical also had strong quarters, Inspire Medical Systems showed weaker performance.
STAAR Surgical Raises Pay for Interim Co-CEO Andrews
STAAR Surgical (STAA) has increased the annual base salary of Interim Co-CEO and CFO Deborah Andrews from $512,000 to $575,000, and her target annual cash bonus from 55% to 60% of base salary, effective June 8, 2026. These adjustments reflect competitive market data and recognition of her contributions to the company. Analysts currently rate STAA as a Buy with a $40.00 price target, though TipRanks' AI Analyst Spark gives it a Neutral rating due to high valuation and near-term uncertainty despite strong trends.
CenterBook Partners LP Buys New Position in STAAR Surgical Company $STAA
CenterBook Partners LP has acquired a new position in STAAR Surgical Company, purchasing 177,974 shares valued at approximately $4.1 million in the fourth quarter. This move comes as STAAR Surgical reported strong quarterly earnings of $0.10 per share and revenue of $93.52 million, both exceeding analyst expectations with a significant year-over-year revenue increase of 119.6%. Despite mixed analyst ratings, with a consensus "Hold" and an average price target of $27.81, several firms have recently increased their price targets for the stock.
STAAR Surgical (STAA) boosts interim co-CEO and CFO Deborah Andrews’ salary and bonus
STAAR Surgical (STAA) has increased the compensation for Deborah Andrews, its Interim Co-Chief Executive Officer and Chief Financial Officer. Effective June 8, 2026, her annual base salary will rise from $512,000 to $575,000, and her target annual cash bonus will increase from 55% to 60% of her base salary. These adjustments reflect a review of market data and acknowledge Ms. Andrews' significant contributions to the company's strategic and operational objectives.
Assessing STAAR Surgical (STAA) Valuation After Recent Share Price Volatility
STAAR Surgical (STAA) has experienced mixed share performance recently but shows strong momentum over the past three months and year, despite longer-term negative returns. The company is currently valued near analyst price targets, with a popular narrative suggesting it is 4.7% undervalued at $29.67 per share, supported by strong cash reserves and no debt. However, a high Price/Sales ratio compared to its industry and peers indicates potential valuation risk if market sentiment shifts.
Assessing STAAR Surgical (STAA) Valuation After Recent Share Price Volatility
STAAR Surgical (STAA) has seen significant share price volatility, with recent declines but strong 90-day and 1-year returns. Valued at US$1.42 billion and trading near analyst targets, the company is considered 4.7% undervalued with a fair value of $29.67 per share, supported by strong cash reserves and no debt. However, valuation risks remain due to its P/S ratio being higher than industry averages and potential challenges from weak China demand or increased competitive pressure.
STAAR Surgical Stock Hits Day Low of $29.03 Amid Price Pressure
STAAR Surgical Co. experienced a 7.36% stock decline, hitting an intraday low of $29.03. Despite this recent volatility and a 11.31% decrease over the past week, the company reported strong annual growth with a 119.59% increase in net sales and a 120.62% rise in net profit. Stakeholder ownership has also increased by 30.34%, indicating growing confidence in the company's underlying financial strength.
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Cogent Biosciences (COGT) and GlaxoSmithKline (GSK)
This article highlights bullish sentiments from analysts on three healthcare companies: Staar Surgical (STAA), Cogent Biosciences (COGT), and GlaxoSmithKline (GSK). John Young CFA of Canaccord Genuity maintained a Buy rating on Staar Surgical, David Nierengarten of Wedbush reiterated a Buy on Cogent Biosciences, and Michael Leuchten from Jefferies upheld a Buy rating for GlaxoSmithKline, each providing price targets and current analyst consensus for the respective stocks.
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Cogent Biosciences (COGT) and GlaxoSmithKline (GSK)
This article highlights bullish sentiments from analysts on three healthcare companies: Staar Surgical (STAA), Cogent Biosciences (COGT), and GlaxoSmithKline (GSK). Specifically, a Canaccord Genuity analyst maintained a Buy rating on Staar Surgical with a $32 price target, a Wedbush analyst maintained a Buy rating on Cogent Biosciences with a $55 price target, and a Jefferies analyst maintained a Buy rating on GlaxoSmithKline with a $67.10 price target. The article details analyst ratings, price targets, and consensus ratings for each company.
Staar Surgical Co (STAA) Stock Down 7.3% -- Now Undervalued? GF Score: 81/100
Staar Surgical Co (STAA) stock fell 7.3% to $29.08 on May 28, 2026, yet GuruFocus assesses it as 6.0% undervalued with a GF Value™ of $30.94 due to its current market price not fully reflecting its estimated intrinsic value. The company boasts a strong GF Score™ of 81/100, excellent momentum, and robust insider buying of $12.3 million in shares over the past three months, signaling insider confidence in future growth despite recent stock volatility. Its forward P/E ratio of 82.2x is also significantly below its 5-year median, suggesting a potential buying opportunity for long-term investors.
Staar Surgical Co (STAA) Stock Down 7.3% -- Now Undervalued? GF Score: 81/100
Staar Surgical Co (STAA) stock fell 7.3%, but GuruFocus's GF Value™ suggests it is 6.0% undervalued with a fair value of $30.94. The company has a strong GF Score™ of 81/100, indicating a promising investment opportunity, further supported by $12.3 million in insider stock purchases over the last three months. Its current forward P/E ratio of 82.2x is below its 5-year median, suggesting a comparatively lower valuation historically.
Assessing STAAR Surgical (STAA) Valuation After A Sharp Multi‑Month Share Price Rebound
STAAR Surgical (STAA) has experienced a significant share price rebound, with a 26% increase over the last month and 78% over three months, despite a 77.8% decline over five years. Analysts currently estimate STAA's fair value at $21.11 per share, suggesting it is overvalued at its current price of $32.47. The company's strong cash reserves and lack of debt provide financial stability, but concerns about execution in key markets, weak consumer demand in China, and potential growth constraints due to cost-cutting remain, raising questions about its future valuation.
Assessing STAAR Surgical (STAA) Valuation After A Sharp Multi‑Month Share Price Rebound
STAAR Surgical (STAA) has seen a significant share price rebound, with a 26% increase in the last month and 78% in three months, despite a long-term decline. Analysts consider the stock, currently trading at $32.47, to be 54% overvalued with a fair value of $21.11, raising questions about whether the recent surge is justified given challenges in key markets and execution scrutiny. The company possesses strong cash reserves which could mitigate risks and support growth, but weak consumer demand in China and potential growth-limiting cost cuts remain concerns.
What's Driving Broadwood Partners' Deep Dive into STAAR Surgical
Activist investor Broadwood Partners is significantly increasing its stake in STAAR Surgical, investing over $12 million recently, following a prior $8.8 million investment, despite rejecting a $1.6 billion acquisition offer from Alcon. Broadwood, now effectively controlling the boardroom, believes STAAR's fundamentals are improving, with an anticipated return to growth and profitability from 2026 onwards. However, STAAR faces considerable challenges including a significant TTM revenue decline, negative profitability, and persistent macroeconomic headwinds in China, leading to a consensus "Reduce" rating from analysts.
STAA stock on track for its fourth straight session of gains – this analyst would rather be early than late on STAAR’s growth story
The article discusses STAAR Surgical Company (STAA) stock, which is showing a fourth consecutive session of gains. An analyst has upgraded STAAR stock to a Buy rating, indicating a strong belief in the company's future growth potential in the ophthalmic market. The analyst highlighted STAAR's position to capitalize on the increasing adoption of implantable contact lenses, suggesting strong growth prospects despite current market skepticism.
STAAR Surgical Announces Participation in Upcoming Investor Conferences
STAAR Surgical Company (NASDAQ: STAA) announced that its management will participate in two upcoming investor conferences: the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026, and a Canaccord Genuity Virtual Fireside Chat on May 27, 2026. Participation for investor meetings is by invitation only, but webcasts for both events will be available on STAAR’s investor website. The company is a global leader in phakic IOLs with its EVO family of Implantable Collamer Lenses for vision correction.
Vision-correction lens maker STAAR hosts May investor talks
STAAR Surgical Company (NASDAQ: STAA) announced its participation in two upcoming investor conferences in May 2026. Management will join the Stifel 2026 Virtual Ophthalmology Forum on May 26 and a Canaccord Genuity Virtual Fireside Chat on May 27, primarily for investor meetings by invitation and webcasts. These events provide an opportunity for investors to learn more about the company, which is a global leader in phakic IOLs for vision correction.
5 must-read analyst questions from STAAR Surgical’s Q1 earnings call
This article highlights key analyst questions from STAAR Surgical's Q1 earnings call. It focuses on inquiries about the company's financial performance, market strategy, and future outlook, providing insights into investor concerns and management responses.
5 Must-Read Analyst Questions From STAAR Surgical’s Q1 Earnings Call
STAAR Surgical reported strong Q1 results, exceeding analyst expectations for revenue, EPS, and EBITDA, attributed to robust sales in China and the EVO+ lens launch. The company's interim Co-CEO noted that operational disruptions from 2025 are largely resolved. Key analyst questions focused on China's market seasonality and competition, inventory levels, and ex-China growth prospects following the expanded U.S. age indication.
STAAR Surgical Q1 2026 Results: Revenue Up 120%, EPS Beats Estimates - News and Statistics
STAAR Surgical announced strong Q1 2026 results, exceeding Wall Street's revenue and EPS forecasts with a 120% sales jump to $93.52 million and non-GAAP EPS of $0.29. The company attributed this success to robust sales in China, early demand for the EVO+ lens, normalized inventory levels, and improved operational efficiencies. Management is cautious about providing short-term guidance but sees continued growth drivers, including expanded U.S. market access and scaling of its Swiss manufacturing facility.
STAAR Surgical (STAA) interim Co-CEO receives PSUs and share tax withholding
STAAR Surgical's interim Co-CEO and CFO, Deborah J. Andrews, reported equity compensation activity related to performance stock units (PSUs) that vested on May 15, 2026. Two tranches of PSUs, totaling 15,699 shares, settled into common stock after performance certification. To cover tax obligations, 5,632 shares were withheld at approximately $32.07 per share, resulting in Andrews directly holding 15,297 shares of STAAR Surgical common stock.
STAAR Surgical (STAA) Is Up 15.2% After EVO+ China Surge Drives Sharp Q1 Profit Rebound – Has The Bull Case Changed?
STAAR Surgical (STAA) reported a significant Q1 2026 profit rebound, with net sales surging to US$93.52 million and achieving a net income of US$5.21 million, primarily driven by strong demand for EVO+ lenses in China and expanded U.S. indications. This performance bolsters the company's investment narrative, emphasizing its potential in lens-based refractive surgery, though it remains exposed to China market volatility and regulatory risks. Despite the positive quarter, the company's fair value is estimated at $21.11, suggesting a 34% downside from its current price, and its strong dependence on China means investors should remain aware of potential policy shifts.
STAAR Surgical (STAA) Is Up 15.2% After EVO+ China Surge Drives Sharp Q1 Profit Rebound – Has The Bull Case Changed?
STAAR Surgical experienced a significant Q1 2026 profit rebound, primarily driven by resurgent demand for its EVO+ lenses in China. This surge, coupled with expanding U.S. indications and cost control measures, transformed the company's profitability. While this bolsters the China recovery story and broadens STAAR's market, the article cautions that the company remains highly dependent on the Chinese market and its associated risks.
GABELLI & Co INVESTMENT ADVISERS INC. Sells 40,000 Shares of STAAR Surgical Company $STAA
GABELLI & Co. Investment Advisers reduced its stake in STAAR Surgical Company by 22.3% in the fourth quarter, selling 40,000 shares. Despite this, STAAR Surgical reported a strong Q1 earnings beat, exceeding revenue estimates by 119.6% year-over-year. Analyst sentiment has shown improvement with several upgrades and higher price targets, though the consensus remains a Hold due to some lingering caution.
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
STAAR Surgical Company reported a strong Q1 2026, with revenue up 119% year-over-year to $93.5M and a net income of $5.2M, driven by China’s market recovery and increased adoption of EVO+ ICL. The company is benefiting from a shift towards lens-based refractive surgery and U.S. market share gains. Despite an elevated valuation, the results suggest potential for sustained growth and margin expansion.
